OverviewSuggest Edit

Adocia is a clinical-stage biotechnology company that specializes in the research and development of innovative formulations of already-approved therapeutic proteins. It operates in the diabetes and other metabolic diseases field. The Company's proprietary technological platform known as BioChaperone is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

TypePublic
Founded2005
HQLyon-3E-Arrondissement, FR
Websiteadocia.com

Latest Updates

Employees (est.) (Jul 2021)116
Share Price (Sept 2021)€9.7(-1%)
Cybersecurity ratingBMore

Key People/Management at Adocia

Olivier Soula

Olivier Soula

Deputy General Manager, R&D Director
Valérie Danaguezian

Valérie Danaguezian

Chief Financial Officer
Olivier Martinez

Olivier Martinez

Director
Laurent Arthaud

Laurent Arthaud

Director
Ekaterina Smirnyagina

Ekaterina Smirnyagina

Director
Gérard Soula

Gérard Soula

President and CEO, Director
Show more

Adocia Office Locations

Adocia has an office in Lyon-3E-Arrondissement
Lyon-3E-Arrondissement, FR (HQ)
115 Avenue Lacassagne
Show all (1)

Adocia Financials and Metrics

Adocia Revenue

Market capitalization (14-Sept-2021)

68.1m

Closing stock price (14-Sept-2021)

9.7
Adocia's current market capitalization is €68.1 m.
Show all financial metrics

Adocia Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Adocia Online and Social Media Presence

Embed Graph

Adocia News and Updates

Adocia to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

LYON, France, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today that Gerard Soula, Adoc…

Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

LYON, France, June 29, 2021 (GLOBE NEWSWIRE) -- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of proteins and peptides, announced today the launch of a Phase 1 clinica…

Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps

LYON, France, May 26, 2021 (GLOBE NEWSWIRE) -- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides announced today that three patent families have been filed for the treatment of…

Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps

LYON, France, May 26, 2021 (GLOBE NEWSWIRE) -- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides announced today that three patent families have been filed for the treatment of…

Arbitration panel rules in favor of Lilly in complaint filed by Adocia

INDIANAPOLIS, Aug. 22, 2019 /PRNewswire/ -- A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY) in a claim filed by Adocia S.A. over the companies' prior collaboration on a rapid-acting insulin. The panel of three arbitrators ruled that Lilly acted...

Adocia Blogs

Bourse & Valeurs #82 TV Program: interview with Gérard Soula on Adocia news

The journalist, Jean-Pierre Vacher, interviewed Gérard Soula, Adocia’s CEO, on biotech news by the end of the year in Lyon Décideurs – Bourse & Valeurs program #82 Topics covered: Spotlight on BioChaperone® Lispro Phase 3 project in China and Adocia’s expanding pipeline in #obesity and #cellular…

@Adocia_Biotech on Twitter!

We are happy to announce the launch of our twitter channel @Adocia_Biotech! Follow @Adocia_Biotech for news, events and see how the team at Adocia is dedicated to develop innovative treatments for diabetes and other metabolic diseases every day.

EASD 2021, Adocia’s Oral Presentation

The 57th EASD Annual Meeting is going to be a virtual event and will take place this year from September 27 until October 1st. AT this occasion, Adocia will be presenting Parts A and B of the study of its product M1Pram: “Ado09, a co-formulation of pramlintide and insulin A21G improves post-prandial…

June 27th at 4pm ET: M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions

ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions which will be held June 25-29, 2021, as a virtual event. Topline results of this positive study were shared in a press release distributed on September 15, 2020. In this oral presentatio…

Listen to the WEBINAR Quality by Design (QbD) / Design of Experiments (DoE) in the context of the development of ADOCIA’s chemical processes, presented by Thomas Cochet

On Tuesday, May 18, Thomas Cochet, Head of Chemical Processes, presented the Quality by Design (QbD)/Design of Experiments (DoE) approach in the context of ADOCIA’s chemical process development. An example with the JMP software! How can the use of experimental designs be used to predict the impact o…

ATTD 2021: Adocia Oral Presentation on M1Pram Wednesday, June 2nd

Next June 2-5, 2021, at the occasion of the Virtual Event ATTD 2021, Adocia is pleased to present the following study: ADO09, A CO-FORMULATION OF PRAMLINTIDE AND INSULIN A21G IMPROVES POST-PRANDIAL GLUCOSE (PPG) VERSUS INSULIN ASPART IN TYPE 1 DIABETES (T1D)  The International Conference on Advanced…
Show more

Adocia Frequently Asked Questions

  • When was Adocia founded?

    Adocia was founded in 2005.

  • Who are Adocia key executives?

    Adocia's key executives are Olivier Soula, Valérie Danaguezian and Olivier Martinez.

  • How many employees does Adocia have?

    Adocia has 116 employees.

  • Who are Adocia competitors?

    Competitors of Adocia include Neuro-Bio, Citryll and Clover Biopharmaceuticals.

  • Where is Adocia headquarters?

    Adocia headquarters is located at 115 Avenue Lacassagne, Lyon-3E-Arrondissement.

  • Where are Adocia offices?

    Adocia has an office in Lyon-3E-Arrondissement.

  • How many offices does Adocia have?

    Adocia has 1 office.